Recently, a CD200R1-targeting antibody, 23ME-00610, was reported to enhance the function of anti-tumor T cells by blocking CD200:CD200R1 binding, thus inhibiting tumor growth while participating in the immune activation pathway (47). This evidence concerns the gene CD200 and neoplasm.